A Unique Case of Secondary Pulmonary Alveolar Proteinosis after E-Cigarette, or Vaping, Product Use–associated Lung Injury
Anna‐Karoline Israel(University of Rochester Medicine), Tanupriya Agrawal(University of Rochester Medicine), Robert Ambrosini, Serban A. Staicu(University of Rochester Medicine), Matthew McGraw(University of Rochester Medicine), Moises J. Velez(Memorial Sloan Kettering Cancer Center)
Cited by 14
Related Papers
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
|Annals of Oncology|2018|588
E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach
|The Lancet Respiratory Medicine|2019|256
Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
|Nature Communications|2021|167
The E-cigarette or Vaping Product Use–Associated Lung Injury Epidemic: Pathogenesis, Management, and Future Directions: An Official American Thoracic Society Workshop Report
|Annals of the American Thoracic Society|2022|134